Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
European Psychiatry, Volume 21, No. 4, Year 2006
Notification
URL copied to clipboard!
Description
Purpose. - Sexual dysfunction in patients with schizophrenia can reduce quality of life and treatment compliance. This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year. Subjects and methods. - Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N = 2638), risperidone (N = 860), quetiapine (N = 142) or haloperidol (N = 188). Results. - Based on patient perception, the odds of experiencing sexual dysfunction during 1 year of therapy was significantly lower for patients treated with olanzapine and quetiapine when compared to patients who received risperidone or haloperidol (all P ≤ 0.001). Females on olanzapine (14%) or quetiapine (8%) experienced a lower rate of menstrual irregularities, compared to females on risperidone (23%) or haloperidol (29%). Significant discordance was evident between patient reports and psychiatrist perception of sexual dysfunction, with psychiatrists underestimating sexual dysfunction (P ≤ 0.001). Conclusion. - These findings indicate clinically relevant differences exist in the sexual side effect profiles of these selected antipsychotics. These factors should be considered when selecting the most appropriate treatment for outpatients with schizophrenia. © 2006 Elsevier SAS. All rights reserved.
Authors & Co-Authors
Dossenbach, Martin
United States, Indianapolis
Eli Lilly and Company
Dyachkova, Yulia
United States, Indianapolis
Eli Lilly and Company
Pirildar, Sebnem
Turkey, Izmir
Ege Üniversitesi
Anders, Martin
Czech Republic, Prague
Charles University
Khalil, Afaf Hamed
Egypt, Cairo
Ain Shams University Hospitals
Araszkiewicz, Aleksander
Poland, Bydgoszcz
Ludwik Rydygier Collegium Medicum in Bydgoszcz
Shakhnovich, Tamara
Russian Federation, Moscow
Psychiatry Hospital n4
Akram, Aly
Saudi Arabia, Jeddah
Suliman Faqueeh Hospital
Pecenak, Jan
Slovakia, Bratislava
Comenius University Medical School
McBride, Margaret
Australia, Sydney
Eli Lilly Australia Pty Ltd.
Treuer, Tamás
United States, Indianapolis
Eli Lilly and Company
Statistics
Citations: 120
Authors: 11
Affiliations: 9
Identifiers
Doi:
10.1016/j.eurpsy.2005.12.005
ISSN:
09249338
Research Areas
Disability
Health System And Policy
Mental Health
Sexual And Reproductive Health
Study Design
Cross Sectional Study
Cohort Study
Participants Gender
Female